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ABSTRACT: Prion diseases are fatal neurodegenerative disorders believed to be transmitted by PrPSc, an
aberrant form of the membrane protein PrPC. In the absence of an established form-specific covalent
difference, the infectious properties of PrPSc were uniquely ascribed to the self-perpetuation properties of
its aberrant fold. Previous sequencing of the PrP chain isolated from PrP(27-30) showed the oxidation
of some methionine residues; however, at that time, these findings were ascribed to experimental limitations.
Using the unique recognition properties of RPrP mAb IPC2, protein chemistry, and state of the art mass
spectrometry, we now show that while a large fraction of the methionine residues in brain PrPSc are
present as methionine sulfoxides this modification could not be found on brain PrPC as well as on its
recombinant models. In particular, the pattern of oxidation of M213 with respect to the glycosylation at
N181 of PrPSc differs both within and between species, adding another diversity factor to the structure of
PrPSc molecules. Our results pave the way for the production of prion-specific reagents in the form of
antibodies against oxidized PrP chains which can serve in the development of both diagnostic and
therapeutic strategies. In addition, we hypothesize that the accumulation of PrPSc and thereafter the
pathogenesis of prion disease may result from the poor degradation of oxidized aberrantly folded PrP.
Many lines of evidence point to PrPSc being the only active
constituent of the infectious prion, the agent that causes fatal
neurodegenerative prion diseases such as scrapie, bovine
spongiform encephalopathy (BSE), and Creutzfeldt-Jakob
disease (CJD) (1). In the absence of convincing data to the
contrary, PrPSc and its normal isoform, PrPC, are believed
to differ from each other only in their high-order structures,
mostly an R-helical fold for PrPC and largely a -sheet
assembly for PrPSc (2). The established covalent modifica-
tions on both prion protein chains include two N-linked
glycosylation sites (residues 181 and 197 in SHaPrP) and a
glycosyl-phosphatidyl-inositol (GPI) moiety, which anchors
the protein molecules to membrane rafts (3). Although some
differences at the sugar moieties were suggested, no “prion-
specific feature” was identified at this level since both the
conversion of PrPC to PrPSc and the propagation of prion
infectivity also occur in the absence of N-linked glycosylation
and of the GPI anchor (4–6). Furthermore, cysteines 179 and
214 are engaged in the single intramolecular disulfide bond
which links two of the three R-helices of PrPC (7). An intact,
oxidized, disulfide bond was suggested to be essential not
only for the conversion of PrPC into PrPSc but also for the
propagation of prion infectivity (8).
Surprisingly, the biochemical search for differential co-
valent modifications on PrPSc is summarized in only one
report. In this seminal work, Stahl et al. sequenced
PrP(27-30), the purified proteinase K (PK) resistant form
of SHaPrPSc (9). Using mass spectrometry and Edman
degradation, they proved that the primary structure of the
infectious core of PrPSc is indeed identical to the one deduced
from the PrP gene sequence and subsequently to that of PrPC.
They also found that either one or two methionines (M206
and/or M213) were present in the form of methionine
sulfoxide (MetO),1 but in the absence of controls such as
recombinant models (recPrP) or purified PrPC, the relevance
of this oxidation could not be assured at that time (9).
Stress-related oxidation of amino acids, in particular
methionines, is more prominent at older ages (10). Con-
comitantly, the activity of enzymes which recycle oxidized
proteins by reducing MetO, methionine reductases, is
compromised at older ages (11). Reactive oxygen species
(ROS) formed during oxidative stress events play a role in
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the pathology of neurodegenerative disorders such as Alzhe-
imer’s and Parkinson’s diseases (12), probably since the
oxidation of proteins by these species alters their hydrophi-
licity and enhances their protease resistance (13). Consistent
with its unique large number of methionines, PrPC has been
assigned a role in the protection of cells from ROS (14, 15).
In this sense, several experimental setups indicated that
recPrP constitutes an excellent target for oxidation (16, 17).
However, the cross talk between PrP oxidation and the
conversion to its -form is unclear. While some experiments
indicate that, as for other proteins (13), oxidation of R-helix-
folded recPrP (modeling for PrPC) favors the formation and
aggregation of an enriched -sheet conformer structure
(reminiscent of PrPSc), other experiments show convincingly
that the oxidization of R-recPrP drastically decreases the rate
and efficiency of the conversion into amyloid-like -recPrP
polymers (18). The last possibility would infer that oxidation
of methionines in PrPSc, as suggested by Stalh et al., occurs
after the conversion of PrPC to the -isoform. Alternatively,
this would also support the idea that the PrPSc chains carrying
the oxidized methionines are the true infectious entities.
Using both the reactivity of IPC2, an R-PrP mAb
recognizing the intramolecular disulfide bond and its proxi-
mal environment in PrPC but not in PrPSc, and mass
spectrometry, we show here, for the first time, that methion-
ine residues in PrPSc are indeed present as methionine
sulfoxides. This is not the case for PrPC or for its recombinant
models (recPrP). Therefore, methionine oxidation constitutes
a specific covalent modification of PrP in its prion state.
Whether oxidation of methionines in the PrP chains is a
requirement for the induction of the proper infectious folding
remains to be established.
MATERIALS AND METHODS
Production of Full-Length recPrP. Full-length chains
corresponding to the mouse, hamster, human, ovine, and
bovine PrP sequences lacking the N- and C-terminal
sequences were expressed from their pET11a construct and
folded to their R-form as described previously (21). Their
-forms were obtained after prolonged incubation in 30 mM
NaAc (pH 5.0) containing 0.2 M NaCl and 3 M urea at
37 °C (19, 20). The rSHaPrP(23-232) N181D and M213S
mutants were generated by site-directed mutagenesis using
QuickChange protocols and the following oligos (only
forward sequences are given): 5′-CGATTGTGTCGACAT-
CACCATCAAGCAGC (N181D) and 5′-GTGGTGGAG-
CAGTCCTGTACCACCCAG (M213S).
Normal and Prion-Infected Brain Homogenates. Brains
from normal and Sc237 prion-infected Syrian hamsters and
of normal and RML-infected C57 black mice were obtained
from the Hadassah Animal Facility. Human brain samples
from control, sporadic CJD cases and from E200K genetic
cases were supplied from the Surveillance Service of
Hadassah Hospital. Control and scrapie-affected ovine brain
samples were provided by the Agriculture Center of the
Israeli Ministry of Agriculture. Normal and prion-containing
brain samples were homogenated at 10% (w/v) in 10 mM
Tris (pH 7.4) and 0.3 M sucrose. Unless stated, proteinase
K (PK) digestions were performed by incubating 50 µL of
10% prion-infected brain homogenates in 40 µg/mL protease
for 1 h at 37 °C. For the SHaPrP(27-30) enrichment, brain
microsomes from infected animals were extracted in TNS
buffer (10 mM Tris, 100 mM NaCl, and 2% Sarkosyl),
cooled for 1 h at 4 °C, and then ultracentrifuged for 1 h at
100000g. Pellets were resuspended in 100 µL of TNS and
digested for 1 h with 100 µg/mL proteinase K. After the
addition of 1 mL of TNS, samples were centrifuged again
for 1 h at 40000 rpm.
Antibody Generation. Full-length R-rMoPrP prepared as
described above in combination with pertussis toxin and
Friend’s adjuvant was used to immunize PrP-ablated mice
(21). Subsequently, spleens from the immunized mice were
processed for the preparation of mAbs. Hybridomas were
screened by an ELISA against rMoPrP and then tested for
immunoblotting. PEPscan analysis was performed for the
identification of R-PrP mAb epitopes (22).
H2O2 Oxidation. Oxidation of rPrP with H2O2 was
performed essentially as described previously (17). Briefly,
recPrP (approximately 2 µM in PBS) was incubated in the
absence or presence of 3, 10, and 50 mM H2O2. After
incubation for 15 min at 37 °C, the reaction was quenched
by addition of 20 mM free methionine.
N-Methylmercaptoacetamide Reduction. Normal and pro-
teinase K-digested prion-infected brain homogenates were
treated with 6 M N-methylmercaptoacetamide (MMA) (23).
After incubation for 15 h at 37 °C, samples were precipitated
with 9 volumes of methanol (1 h, -80 °C) and then
centrifuged (10000 rpm, 30 min, 4 °C). For H2O2-treated
and untreated recPrP samples, MMA was added at a
concentration of 2 M in PBS. After incubation for 2 h at
37 °C, proteins were mixed with 40 µg of BSA and
precipitated with 9 volumes of methanol. For both types of
samples, pellets were washed twice with methanol and
processed for SDS-PAGE analysis in the absence of
-mercaptoethanol.
In Situ PNGase Digestion. Enzymatic deglycosylation was
adapted from ref 24. Briefly, after electrotransference, the
nitrocellulose membranes were blocked in PBS containing
3% BSA for 30 min and then incubated for 3 h with 50 mM
sodium phosphate (pH 7.2) containing PNGase F at a
concentration of either 20 units/mL (Sigma) or 500 units/
mL (New England Biolabs). After being washed, the
membranes were blocked in milk and immunoblotted with
the appropriate anti-PrP mAbs.
Mass Spectrometry. Gel bands from relevant PrP chains
were processed for tryptic digestion as described previously
(25). Subsequently, the peptide mixture was solid phase
extracted with a C18 resin-filled tip (ZipTip, Millipore,
Billerica, MA) and nanosprayed into the Orbi-trap MS
system in a 50% CH3CN/1% CHOOH solution. Mass
spectrometry was carried out with Orbi-trap (Thermo Finni-
gen) using a nanospray attachment (26). Data analysis was
carried out using Bioworks version 3.3, and database searches
were performed with the sequest package and the Mascot
package (Matrix Science).
SDS-PAGE, Western Blotting, and ELISA. Proteinase
K-treated or untreated brain homogenates as well as recom-
binant PrP protein samples were denatured in the presence
or absence of me and then subjected to SDS-PAGE using
either 12% (brain homogenates) or 14% (recombinant PrP
chains) acrylamide gels. For immunoblotting, the gels were
transferred to nitrocellulose membranes and developed with
alkaline phosphatase-labeled anti-mouse reagents. For ELISA
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tests, recombinant PrP and MOG (myelin oligodendrocyte
glycoprotein) proteins (5 µg/mL) were bound to the wells
of a 96-well plate and reacted with a 1:3000 dilution of IPC1,
IPC2, and a control mAb glycoprotein. Measurements were
conducted in triplicate, and displayed data correspond to the
average of two independent experiments.
RESULTS
Recognition of PrP by IPC2 Requires an Oxidized Disul-
fide Bond. Our interest in the search for a prion-specific
covalent modification resulted from an investigation into the
peculiar properties of IPC2, an anti-PrP mAb prepared in
our laboratory against R-rMoPrP(23-230). As depicted in
Figure 1, both IPC2 and 6H4 mAb easily recognized rPrPs
from an array of species (27). However, when probed with
brain homogenates, as opposed to 6H4, IPC2 reacted only
with the non- and monoglycosylated chains of MoPrPSc and,
to a lesser extent, of SHaPrPSc. These results suggest that
the IPC2 epitope comprises a highly conserved part of the
PrP sequence, as shown by its activity against all recPrPs,
but that a modification present on native PrPSc precludes the
recognition of some of its denatured chains by this antibody.
PEPscan analysis (24) did not identify any linear PrP
sequence as the IPC2 epitope, whereas the test easily
identified residues 144-151 of the PrP sequence as the
epitope for the anti-PrP mAb IPC1 (Figure 2A). We next
tested whether the IPC2 epitope could comprise the disulfide
bond between C179 and C214. Figure 2B shows that while
the detection of the PrP polypeptide by IPC1 was unaffected
by the presence or absence of -mercaptoethanol, the
detection of recPrP by IPC2 was significantly improved in
the absence of the reducing agent, and it was mostly
abolished by iodoacetamide blockage of the reduced cys-
teines. These results indicate that an intact disulfide bond is
required for the recognition of PrP forms by IPC2.
Figure 2C depicts the differential reactivity of IPC2 in
comparison with those of other anti-PrP antibodies with
normal and prion-infected brain samples immunoblotted in
the absence of reducing agents. As for PrPSc, IPC2 recognized
the non- and monoglycosylated bands of rodent PrPC, albeit
with an affinity lower than those of the other anti-PrP
antibodies tested. Most intriguingly, IPC2 also recognized,
with low affinity, PrP forms of human and ovine normal brain
homogenates, while no protease resistant PrP of these species
was revealed by this antibody. This further suggests that a
prion-specific covalent modification may hinder the recogni-
tion of PrPSc forms by IPC2.
Oxidation of Methionine Residues Impairs the Recognition
of PrP by IPC2. To gain insight into the nature of the
modification preventing IPC2 recognition, we first looked
into the amino acid residues around the PrP disulfide bond
(Figure 2B). Sequence differences at residues 183 (V/I) and
215 (T/I/V) between species were first observed, but since
IPC2 recognizes all recPrP chains tested (Figure 1A), these
residues are unlikely to carry the chemical modification
impeding the recognition.
Almost adjacent to C179 is N181, which can provide steric
repulsion if it is glycosylated or an N-to-D deamidation if it
is enzymatically deglycosylated. On the other side of the
disulfide bond (C214) we found M213, which was suggested
to be present in PrPSc in an oxidized form (9). To investigate
whether modifications in one of these sites may affect the
recognition of PrPSc by IPC2, we prepared the rSHaPrP-
(23-232) N181D and rSHaPrP(23-232) M213S mutants.
Figure 3B shows both by an immunoblot and by an ELISA
that while IPC2 readily recognized the rSHaPrP(23-232)
N181D peptide, the M213S substitution abolished the
recognition of PrP by IPC2. These results indicate that while
the IPC2 epitope comprises M213, N181 is not essential for
the recognition of PrP by this mAb. Nevertheless, high levels
of glycosylation on this site may still interfere sterically with
the reactivity of the IPC2 antibody (see below).
We next tested whether modification by oxidation of M213
may hinder the recognition of PrP by IPC2, which was the
case for the substitution of this amino acid residue with Ser.
For this effect, we oxidized both full-length rMoPrP(23-230)
and rSHaPrP(23-232), folded in either the R- or -form (28),
with increasing concentrations of H2O2 as described previ-
ously (17). As a control for the reversibility of oxidation,
the samples oxidized with 50 mM H2O2 were divided into
two aliquots and one of them was reduced with N-meth-
ylmercaptoacetamide (MMA), a reagent highly specific for
the chemical reduction of methionine sulfoxide (23). Un-
treated, oxidized, and MMA-treated samples were then
precipitated with methanol, washed extensively, analyzed by
SDS-PAGE in the absence of -mercaptoethanol, and then
immunoblotted. Figure 3C shows the results of the oxidation-
reduction experiments for the rSHaPrP(23-232) chain,
folded to both the R- and -folds. Oxidation of the protein
forms did not affect their recognition by IPC1, but the
oxidative treatment caused a size increase, which was
reversed following the reduction with MMA. Interestingly,
oxidation of R-rSHaPrP(23-232) was more efficient than
that of -rSHaPrP(23-232), at least as judged by the
extension of the size enhancement (apparent at 3 mM H2O2
for the R-form but requiring 50 mM in the case of the
-form). Immunoblotting the same samples with IPC2 shows
a H2O2 concentration-dependent decrease in the degree of
recognition of the PrP chains, which parallels the increase
in the molecular size detected by IPC1. Again, such a
decrease in the PrP immunoreactivity was more efficient for
the R-form than for the -form and, in both cases, was
reversed by MMA. Surprisingly, and consistent with previous
results (17), the recognition of rSHaPrP(23-232) with RPrP
mAb 3F4, whose epitope comprises two methionines, M109
and M112, was not affected by oxidation (not shown).
Methionine Residues in PrPSc Are Strongly Oxidized.
Given the relevance of methionine oxidation, in particular
of M213, with respect to the recognition of distinct PrP forms
FIGURE 1: PrP recognition by IPC2 required an intact disulfide bond.
Differential immunoreactivity of IPC2 and 6H4 anti-PrP mAbs
against (1) hamster, (2) mouse, (3) bovine, (4) ovine, and (5) human
PrP from proteinase K-digested 10% (w/v) brain homogenates (10
µL) and recombinant chains (30 ng). Samples were denatured under
reducing conditions before SDS-PAGE analysis.
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by IPC2, we then analyzed the oxidation state of the different
methionine residues in PrP forms by MS/MS using the
trypsin-digested Coomassie blue-stained gel bands (Figure
4A). The tested samples included enriched SHaPrP(27-30),
untreated R-rSHaPrP(23-232), and R- and -rSHaPrP-
(23-232) forms oxidized with 50 mM H2O2. Of the different
PrP tryptic peptides, we focused on those corresponding to
residues 111-136 and 199-220.
Figure 4B describes the results obtained for the 199-220
tryptic peptide (VVEQMCTTQYQK), which is part of helix
C of the PrP structure and contains M213 (29). We found
that while this residue was not oxidized in the untreated
recPrP, it becomes totally replaced by methionine sulfoxide
(MetO) in the peptides obtained from H2O2-treated PrP
chains. These results reinforced the conclusions of the
immunoblotting experiments depicted in Figure 3C, in which
IPC2 did not react with oxidized recPrP due to the oxidation
of M213. They also indicate that Met/MetO oxidation is
indeed an intrinsic feature of the sample under analysis and
not a side reaction due to the biochemical manipulations
required for MS/MS studies. The analysis of the band
corresponding to the fully glycosylated PrP(27-30) revealed
an oxidation pattern similar to that previously described by
Stahl et al. (9), indicating the presence of MetO213 in a
considerable fraction of HaPrPSc molecules as an intrinsic
feature.
Figure 4C shows the MS/MS results corresponding to the
region of residues 111-136 (HMAGAAAAGAVVGGLG-
GYMLGSAMSR), which contains M112, M129, and M134.
This peptide is part of the amyloidogenic region of PrP and
also contains residue M129, which is an important polymor-
phic site modulating the susceptibility to disease acquisition
and the disorder phenotype in humans (30). As depicted in
the figure, while this region appears largely unaltered in
untreated recPrP [only a negligible fraction of molecules
exhibit all Met as MetO, probably resulting from the Cu(II)-
catalyzed oxidative folding (28)], H2O2 treatment of the R-
and -forms causes the quantitative formation of MetO (M/Z
804 representing MetOx3). At this point, the harshness of
the oxidation protocol used impedes the assessment of
whether this region exhibits a different predisposition to
oxidation in the distinct folds. In contrast to untreated recPrP,
the peptides from HaPrPSc lack any nonoxidized Met (Figure
3C). However, opposed to the oxidized recPrP samples, only
a subpopulation of chains of PrP(27-30) were oxidized at
all Met residues. Interestingly, MetO129 appears only when
all the other Met residues of this peptide are oxidized. This
suggests that PrPSc aggregates are a heterogeneous mixture
of chains exhibiting a complex pattern of Met/MetO
combinations.
Differential Oxidation of Methionines in PrPC and PrPSc.
The observed oxidation pattern implies that PrPC may also
FIGURE 2: IPC2 epitope that comprises an oxidized disulfide bond. (A) PEPscan analysis of IPC1 (bottom) and IPC2 (top) anti-PrP mAbs.
(B) Effect of reversible (+me) and irreversible (+me IAcNH2) reduction of disulfide bonds on the recognition of recMoPrP(23-230) by
IPC1 and IPC2 analyzed by dot blot. Blot loads correspond to 10 ng of protein. The analysis displayed in panels A-C was carried out in
duplicate, varying both the sample source and the batch. (C) Typical immunoblots of normal (N) and prion-infected brain homogenates
before (Sc) or after proteinase K digestion (+) of mouse (Mo), hamster (Ha), human (Hu), and ovine (Ov) samples with 6H4, IPC1, and
IPC2 anti-PrP mAbs. Lanes correspond to the load of 10 µL of the original 10% (w/v) homogenate. All samples were prepared in the
absence of reducing reagents.
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be a good substrate for oxidation. However, due to the
complex biochemical manipulations required for its purifica-
tion, the direct analysis by mass spectrometry to establish
the oxidation status of the diverse Met residues in native
PrPC is far from trivial (31, 32). Nevertheless, we can gain
insight into the oxidation status of M213 by utilizing the
peculiar reactivity properties of IPC2. This can be done by
testing whether chemical reduction of MetO, alone or in
combination with in situ PNGase F-catalyzed deglycosyla-
tion, would allow the recognition of the previously unde-
tected PrP chains by IPC2. For this purpose, normal (for
PrPC) and proteinase K-digested prion-infected (for PrPSc)
brain homogenates were incubated in the absence and
presence of MMA, then resolved by SDS-PAGE in the
absence of -mercaptoethanol, and transferred to nitrocel-
lulose membranes. In contrast to the irreversibility of the
MetO reduction by MMA, Cys residues undergo reversible
oxidation as required for recognition by IPC2. Subsequently,
nitrocellulose membranes comprising the MMA-treated and
untreated samples were incubated in the presence or absence
of PNGaseF, to test the relative change in the recognition
of individual PrP bands.
Figure 5A shows the results of these experiments for PrPSc.
In both MoPrPSc and HaPrPSc, reduction with MMA rendered
the fully glycosylated PrP chains partially recognizable by
IPC2. These results are consistent with the mass spectrometry
analysis indicating the oxidation of M213 in a large fraction
of HaPrPSc chains. Interestingly, in situ deglycosylation also
favors the recognition of these PrP forms by IPC2. As
depicted in the figure, digestion with PNGase F in the
absence of MMA treatment had no effect on the recognition
of PrPSc bands by IPC2 in both MoPrPSc and HaPrPSc,
indicating that oxidation of M213 is a definite obstacle for
the recognition of PrPSc bands by this antibody. The most
interesting results were obtained for the HuPrPSc samples.
While the untreated prion form of the human PrP was totally
undetected by IPC2, MMA reduction primarily revealed the
band corresponding to monoglycosylated PrPSc. It was only
after an additional PNGase F digestion that the diglycosylated
chain of HuPrPSc was revealed by the IPC2 antibody. Similar
results were obtained for OvPrPSc samples (not shown).
These results suggest that in species other than rodents, M213
is also present as MetO in the non- and monoglycosylated
PrPSc chains.
Opposite results were obtained for samples containing
PrPC (Figure 5B). In this case, reduction with MMA did
not change the recognition pattern of PrPC by IPC2 while
FIGURE 3: Oxidation of PrP M213 hinders IPC2 recognition. (A) SHaPrP sequence of the segments of helices B and C in the proximity of
the disulfide bond. (B) IPC2 specificity probed by a Western blot and an ELISA using wild-type rSHaPrP(23-232) and its N181D and
M213S mutants. (C) Effect of the oxidation with H2O2 and/or reduction with MMA of rSHaPrP(23-232) chains folded to their R- and
-forms on its recognition by IPC1 and IPC2 anti-PrP mAbs. Samples were denatured in the absence of me before their SDS-PAGE
analysis.
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deglycosylation was sufficiently strong to allow the
identification by IPC2 of the chain corresponding to the
highest-molecular weight band of PrPC in several species.
These results indicate that as opposed to the case in PrPSc,
M213 is not oxidized in PrPC.
DISCUSSION
We have shown here that while methionine residues are
oxidized in -fold PrPSc, this is not the case for its R-helical
form, PrPC. This finding indicates that the prion isoforms
FIGURE 4: Proteinase K resistant SHaPrPSc and rSHaPrP(23-232) differ in their oxidation state of methionine residues. (A) Coomassie blue
bands excised for trypsin digestion and mass spectrometry analysis. Typical mass spectrometry (MS/MS) spectra of the SHaPrP tryptic
peptides corresponding to residues (B) 209-213 and (C) 111-136. Analysis was performed in duplicate using at least two independent
samples.
FIGURE 5: Differences in (A) proteinase K resistant PrPSc and (B) PrPC by IPC2 are modulated by methionine oxidation and glycosylation.
Mouse (Mo), hamster (Ha), and human (Hu) brain homogenates were incubated in the absence and presence of MMA, before electrophoretic
analysis in the absence of me. After electrotransfer, nitrocellulose membranes were either directly blocked or in situ-digested with PNGase
F before being immunoblotted with IPC1 (mouse and hamster) or 6H4 (human) anti-PrP mAbs. Displayed data are the typical results for
three independent analyses. Lane loads correspond to 10 µL of brain homogenates.
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differ not only in their conformation but also in their covalent
structure, constituting the first evidence of a prion-specific
covalent signature. Our results pave the way for the produc-
tion of prion-specific reagents in the form of antibodies
against oxidized PrP peptides. They also suggest new
strategies for the search of prion-related prophylactic thera-
pies. Most importantly, the interaction between ROS and the
metabolism of the prion proteins mechanistically relates
prion-induced neurodegeneration with the pathogenesis of
other conditions affected by the oxidative state of cells, such
as amyotrophic lateral sclerosis, as well as Alzheimer’s and
Parkinson’s diseases (33, 34).
From a structural point of view, while conversion of PrPC
into PrPSc has been uniquely ascribed to a conformational
change, the finding of a covalent modification in the prion
state of PrP allows new inducing or stabilizing factors to
play a role in the complex process of prion formation. In
this sense, since oxidized methionines (in particular M129
and M213) are contained in the chain regions identified as
amyloidnucleatingsitesandprotectedfromthesolvent (35,36),
it seems reasonable to propose that oxidation, which mainly
occurs on exposed residues, takes place when PrP is partially
unfolded.
Our results also support the notion that the prion aggregate
comprises a variety of PrP chains differing from each other
in the number and position of oxidized methionines. This
heterogeneity may correlate with diverse pathways of prion
generation. For instance, oxidation can take place during the
formation of the -PrP molecules present in normal brain
(37) or otherwise during PrPC misfolding.
Our results show that while R-recPrP is readily oxidized
by H2O2, this is not the case for the PrPC present in brains.
This suggests a mechanism in which oxidized PrPC is
efficiently reduced by the methionine sulfoxide reductase
system, is rapidly degraded, or both. In contrast, the oxidized
state of PrPSc indicates that this form is a poor substrate for
the methionine sulfoxide reductase systems or that the
activity of these enzymes is impaired during disease, as in
the case of aging (10). Such oxidized PrPSc molecules may
consequently promote their perpetuation by inhibition of the
proteasome activity (38), therefore allowing the accumulation
of additional aberrantly oxidized and folded PrP molecules
(39, 40).
Lastly, whether the efficiency of the infectivity transmis-
sion and the properties of prion strains are related to a specific
PrP methionine sulfoxide pattern remains to be established.
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